Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study.
Thirty patients with familial defective apolipoprotein B-100 were treated in a two-period (8 weeks each) cross-over study with pravastatin and gemfibrozil. Cholesterol, LDL cholesterol, and apo B were reduced by 20-25% (P < 10(-4)) by pravastatin and by 4-6% by gemfibrozil (pravastatin vs. gemfibrozil: P < 10(-4)). Response to pravastatin was variable and not correlated to gender, age, or apo E genotype. Gemfibrozil lowered triglycerides by 25% (P < 10(-4)) and raised HDL cholesterol by 11%. The effects of pravastatin on these two interrelated variables were significantly smaller. Both drugs increased Lp(a) significantly by about 10%. The LDL cholesterol lowering effect of pravastatin in patients with FDB is similar to that observed in patients with familial hypercholesterolemia.
Hansen
P S
PS
Department of Internal Medicine and Cardiology A, Aarhus Amtssygehus University Hospital, Denmark.
Meinertz
H
H
Gerdes
L U
LU
Klausen
I C
IC
Faergeman
O
O
D000328:Adult; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000235:genetics*; D018592:Cross-Over Studies; D005260:Female; D015248:Gemfibrozil / Q000627:therapeutic use*; D006579:Heterozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D017035:Pravastatin / Q000627:therapeutic use*; D013223:Statistics as Topic
D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D017035:Pravastatin; D015248:Gemfibrozil